Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Key Takeaways Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined.The ...

Gilead Sciences (Nasdaq: GILD) reported flat revenues for the first quarter of 2025, with total sales reaching $6.7 billion, ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

Sales of cancer drug Trodelvy fell 5% to $293 million, below analysts' estimates of $362 million, due to pricing and ...

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing, and care, ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Gilead Sciences (GILD) reported first quarter earnings that topped analyst estimates, but its revenue in the quarter fell ...

Morgan Stanley raised the firm’s price target on Gilead (GILD) to $135 from $130 and keeps an Overweight rating on the shares. The company ...